Boehringer initiates trial of novel SARS-CoV-2 neutralising antibody
In pre-clinical studies, BI 767551 (DZIF-10c) has demonstrated promising virus neutralising properties. Credit: visuals3Dde from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
